Xie Silun, Wu Zhengyi, Zhou Liang, Liang Yingqing, Wang Xiaohua, Niu Lizhi, Xu Kecheng, Chen Jibing, Zhang Mingjie
Research and Development Department, Shenzhen Hank Bioengineering Institute, Shenzhen 518004, China,
Department of Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China,
Onco Targets Ther. 2018 Oct 25;11:7345-7352. doi: 10.2147/OTT.S166962. eCollection 2018.
For advanced hepatocellular carcinoma (HCC) patients, liver transplantation (LT) is an optimal treatment with limitation of high risk of tumor recurrence related to the immunosuppressive chemotherapy as usually recommended. In this study, a 29-year-old man suffered from HCC recurrence after LT. He underwent radiotherapy (total dose: 45 Gy) but had no significant response. Then, he received iodine-125 seed implantation combined with allogenic natural killer (NK) cell immunotherapy. Liver function, immune function, circulating tumor cell counts and computed tomography scans were evaluated to determine the clinical effect. We found that this combined treatment produced enhanced immune function of the patient and reduction in tumor size. This is the first report of an efficacy and safety study about clinical regimen comprising allogenic NK cell immunotherapy combined with iodine-125 seed implantation for the treatment of HCC recurrence after LT.
对于晚期肝细胞癌（HCC）患者，肝移植（LT）是一种最佳治疗方法，但通常推荐的免疫抑制化疗会带来肿瘤复发的高风险。在本研究中，一名29岁男性在肝移植后出现肝癌复发。他接受了放射治疗（总剂量：45 Gy），但没有明显效果。随后，他接受了碘-125粒子植入联合异体自然杀伤（NK）细胞免疫治疗。通过评估肝功能、免疫功能、循环肿瘤细胞计数和计算机断层扫描来确定临床效果。我们发现这种联合治疗增强了患者的免疫功能并缩小了肿瘤大小。这是关于异体NK细胞免疫治疗联合碘-125粒子植入治疗肝移植后肝癌复发的临床方案的疗效和安全性研究的首次报告。
